- Home
- BIIB vs BBDO Comparison
BIIB vs BBDO Comparison
Compare BIIB & BBDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BBDO
- Stock Information
- Founded
- BIIB 1978
- BBDO 1943
- Country
- BIIB United States
- BBDO Brazil
- Employees
- BIIB N/A
- BBDO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BBDO Major Banks
- Sector
- BIIB Health Care
- BBDO Finance
- Exchange
- BIIB Nasdaq
- BBDO Nasdaq
- Market Cap
- BIIB 18.7B
- BBDO 28.5B
- IPO Year
- BIIB 1991
- BBDO N/A
- Fundamental
- Price
- BIIB $147.94
- BBDO $2.85
- Analyst Decision
- BIIB Buy
- BBDO Strong Buy
- Analyst Count
- BIIB 25
- BBDO 4
- Target Price
- BIIB $183.05
- BBDO $2.55
- AVG Volume (30 Days)
- BIIB 1.6M
- BBDO 46.2K
- Earning Date
- BIIB 10-30-2025
- BBDO 10-29-2025
- Dividend Yield
- BIIB N/A
- BBDO 4.42%
- EPS Growth
- BIIB 31.67
- BBDO 58.81
- EPS
- BIIB 10.45
- BBDO 0.36
- Revenue
- BIIB $9,997,000,000.00
- BBDO $16,114,445,927.00
- Revenue This Year
- BIIB $2.00
- BBDO $77.46
- Revenue Next Year
- BIIB N/A
- BBDO $7.42
- P/E Ratio
- BIIB $14.13
- BBDO $8.53
- Revenue Growth
- BIIB 3.36
- BBDO 27.09
- 52 Week Low
- BIIB $110.04
- BBDO $1.71
- 52 Week High
- BIIB $187.58
- BBDO $3.00
- Technical
- Relative Strength Index (RSI)
- BIIB 55.99
- BBDO 55.01
- Support Level
- BIIB $141.70
- BBDO $2.71
- Resistance Level
- BIIB $147.48
- BBDO $2.95
- Average True Range (ATR)
- BIIB 3.94
- BBDO 0.09
- MACD
- BIIB -0.61
- BBDO 0.00
- Stochastic Oscillator
- BIIB 33.73
- BBDO 66.67
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BBDO Banco Bradesco Sa (each representing one Common Share)
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.